# Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies

> **NCT00256191** · PHASE1 · COMPLETED · sponsor: **Cortice Biosciences, Inc.** · enrollment: 45 (—)

## Conditions studied

- Neoplasms
- Hodgkin's Disease
- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** TPI 287 Injection

## Key facts

- **NCT ID:** NCT00256191
- **Lead sponsor:** Cortice Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** —
- **Final completion:** 2007-02
- **Target enrollment:** 45 (—)
- **Last updated:** 2007-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00256191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00256191, "Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00256191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*